Currently, Cardiff Oncology Inc [CRDF] is trading at $2.97, up 2.77%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CRDF shares have gain 5.69% over the last week, with a monthly amount glided 15.56%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cardiff Oncology Inc [NASDAQ: CRDF] stock has seen the most recent analyst activity on January 05, 2026, when Noble Capital Markets initiated its Outperform rating and assigned the stock a price target of $12. Previously, Ladenburg Thalmann started tracking the stock with Buy rating on July 08, 2025, and set its price target to $19. On June 24, 2025, Jefferies initiated with a Hold rating and assigned a price target of $3.50 on the stock. Craig Hallum started tracking the stock assigning a Buy rating and suggested a price target of $8 on September 06, 2024. William Blair initiated its recommendation with an Outperform. Robert W. Baird started tracking with an Outperform rating for this stock on December 08, 2021, and assigned it a price target of $19.
This stock has fluctuated between a low of $1.90 and a high of $4.99 over the last 52 weeks. Cardiff Oncology Inc [NASDAQ: CRDF] shares were valued at $2.97 at the most recent close of the market.
Analyzing the CRDF fundamentals
Trailing Twelve Months sales for Cardiff Oncology Inc [NASDAQ:CRDF] were 0.50M which represents -27.27% decline. Gross Profit Margin for this corporation currently stands at -22.11% with Operating Profit Margin at -107.2%, Pretax Profit Margin comes in at -100.64%, and Net Profit Margin reading is -100.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.79, Equity is -0.77 and Total Capital is -1.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cardiff Oncology Inc [NASDAQ:CRDF] is 4.20. In addition, the Quick Ratio stands at 4.20 and the Cash Ratio stands at 0.69. Considering the valuation of this stock, the price to sales ratio is 400.12, the price to book ratio is 4.08.
Transactions by insiders
Recent insider trading involved PACE GARY W, Director, that happened on Jul 30 ’25 when 0.28 million shares were purchased. Director, PACE GARY W completed a deal on Jul 30 ’25 to buy 15000.0 shares.
